Essoras

Essoras is a precision medicine company focused on improving oncology treatment outcomes through the analysis of extracellular vesicles (EVs). Spun out from Johns Hopkins University, the company utilizes a proprietary liquid biopsy platform to isolate and characterize EVs, which serve as rich sources of biomarkers for predicting drug response. By identifying which patients are most likely to benefit from specific therapies, Essoras aims to reduce trial-and-error in cancer treatment and accelerate the development of personalized medicines. The company's technology is designed to be integrated into clinical trials and routine patient care to optimize therapeutic selection.